Sarcoïdose in patient with chronic hepatitis C treated with pegylated interferon

Induced sarcoïdosis during therapy with interferon for chronic viral hepatitis C involves mainly by isolated cutaneous lesions or with lung lesions. Systemic forms are very rare. We report an observation. A 50-year-old patient developed a systemic sarcoïdosis two months after the end of treatment fo...

Full description

Saved in:
Bibliographic Details
Published inRevue de pneumologie clinique Vol. 70; no. 6; pp. 362 - 365
Main Authors Moudden, M K, Ziadi, T, Al Bouzidi, A, Ouarssani, A, Hadri, L, El Baaj, M
Format Journal Article
LanguageFrench
Published France 01.12.2014
Subjects
Antiviral Agents - adverse effects
Drug Therapy, Combination
Hepatitis C, Chronic - drug therapy
Humans
Interferon-alpha - adverse effects
Polyethylene Glycols - adverse effects
Recombinant Proteins - adverse effects
Ribavirin - adverse effects
Ribavirin - therapeutic use
Sarcoidosis - chemically induced
Tomography, X-Ray Computed
Sarcoïdose
Hépatite C
Interféron pégylé
Sarcoidosis
Hepatitis C
Pegylated interferon
Online AccessGet full text

Cover

More Information
Summary:Induced sarcoïdosis during therapy with interferon for chronic viral hepatitis C involves mainly by isolated cutaneous lesions or with lung lesions. Systemic forms are very rare. We report an observation. A 50-year-old patient developed a systemic sarcoïdosis two months after the end of treatment for hepatitis C with pegylated interferon and ribavirin with lung, joint and hepatic manifestations. After starting corticosteroid therapy, the evolution was favourable. Induced sarcoïdosis by interferon therapy is rare, treatment necessitates stopping interferon, and sometimes corticosteroid therapy.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0761-8417
DOI:10.1016/j.pneumo.2014.07.001